PSTV•benzinga•
Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $20.5
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 5, 2025 by benzinga